Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Share-based Compensation (2024 - 2025)

Indivior Pharmaceuticals has reported Share-based Compensation over the past 2 years, most recently at $5.0 million for Q4 2025.

  • Quarterly results put Share-based Compensation at $5.0 million for Q4 2025, down 16.67% from a year ago — trailing twelve months through Dec 2025 was $26.0 million (up 8.33% YoY), and the annual figure for FY2025 was $26.0 million, up 8.33%.
  • Share-based Compensation for Q4 2025 was $5.0 million at Indivior Pharmaceuticals, down from $7.0 million in the prior quarter.
  • Over the last five years, Share-based Compensation for INDV hit a ceiling of $8.0 million in Q2 2025 and a floor of $5.0 million in Q4 2025.